AI/ML Innovations Inc. Announces Grant of U.S. Patent Protecting Core ECG Signal-Processing Architecture

Rhea-AI Summary

AI/ML Innovations (AIMLF) announced a U.S. patent allowance (U.S. Patent No. 12,465,266) on November 11, 2025, covering its core machine‑learning architecture for ECG denoising, beat‑level wave morphology identification, and mapping patterns to cardiac rhythm conditions.

The allowance is the first granted patent in AIML's IP portfolio, is claimed broadly without substantive narrowing for prior art, and is said to support the company's MaxYield™ and CardioYield™ products as AIML advances clinical validation, regulatory pathways, and commercial deployment.

Positive

• U.S. patent allowance granted (No. 12,465,266) on November 11, 2025
• Core ECG architecture protection for denoising and wave‑morphology identification
• First allowance in AIML's IP portfolio, implying patent momentum
• Supports products MaxYield and CardioYield for clinical deployment
• Broader claims allowed without substantive narrowing for prior art

Negative

• None.

News Market Reaction

-4.70%

1 alert

-4.70% News Effect

On the day this news was published, AIMLF declined 4.70%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

• Patent validates AIML's novel neural-network approach to denoising and mapping ECG signals, powering MaxYield™ and CardioYield™.

• Reinforces competitive advantage as the Company advances commercialization and regulatory pathways.

TORONTO, ON / ACCESS Newswire / November 11, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leader in AI-powered physiological signal interpretation, is pleased to announce that through its wholly owned subsidiary NeuralCloud Solutions Inc. ("Neural Cloud") the United States Patent and Trademark Office has issued a Notice of Allowance (U.S. Patent No. 12,465,266) for its patent application covering the core machine-learning architecture underlying Neural Cloud's electrocardiogram ("ECG") wave-property identification engine. The allowed claims protect the Company's proprietary approach for denoising ECG signals, identifying beat-level wave morphology, and associating those patterns with clinically meaningful cardiac rhythm conditions.

This patent represents the first allowance among several pending applications in AIML's intellectual property portfolio.

The allowed patent claims protect AIML's proprietary systems and methods for advanced ECG signal interpretation.

• These innovations cover the Company's novel approach to extracting clinically meaningful information from raw cardiac signals - enabling the identification of key waveform features and rhythm patterns with high precision.

• The technology also supports decision-support and clinical workflow integration, helping translate complex ECG data into actionable insights for improved outcomes.

"This patent represents an exciting milestone for our platform," said Esmat Naikyar, President of Neural Cloud. "The core signal-processing and wave-morphology identification engine is what enables our downstream products-including MaxYield™ and CardioYield™-to deliver high-fidelity, clinically interpretable cardiac insights. The allowance validates both our technical innovation and our long-term vision for precision cardiac interpretation."

Paul Duffy, Executive Chairman and CEO of AIML, added: "This reflects meaningful progress for the Company. The patent was allowed with broad claims and without the need for substantive narrowing due to prior art, reinforcing the novelty of our approach. It provides strong protection around the architecture we have developed, positioning AIML with a meaningful competitive advantage as we advance commercialization. We are actively continuing to expand our IP portfolio, with additional filings underway as we accelerate product deployment globally."

This allowance strengthens AIML's intellectual property position as the Company advances its clinical validation, regulatory, and commercial strategies across cardiology, remote monitoring, telehealth, and clinical research applications.

About AI/ML Innovations Inc.

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca .

Contact:
Blake Fallis (778) 405-0882

On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services and the Company's ability to secure any additional patents related to its products or technology. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

SOURCE: AI/ML Innovations, Inc.

View the original press release on ACCESS Newswire

FAQ

What did AIMLF announce on November 11, 2025 about intellectual property?

AIMLF announced a U.S. patent allowance (U.S. Patent No. 12,465,266) covering its ECG signal‑processing machine‑learning architecture.

Which AIMLF products are supported by the new U.S. patent No. 12,465,266?

The patent is described as supporting AIMLF's MaxYield™ and CardioYield™ products by protecting ECG denoising and wave‑morphology extraction.

How does the patent allowance affect AIMLF's commercialization and regulatory plans?

AIMLF said the allowance strengthens its IP position as it advances clinical validation, regulatory pathways, and commercial deployment in cardiology and remote monitoring.

What technical capabilities does AIMLF's allowed patent protect for AIMLF (AIMLF)?

The allowed claims cover denoising raw ECG signals, identifying beat‑level wave morphology, and associating patterns with clinically meaningful rhythm conditions.

Is the U.S. patent allowance the only patent in AIMLF's portfolio?

No; the company said this is the first allowance among several pending applications in its intellectual property portfolio.

Does AIMLF say the granted patent was narrowed during prosecution for prior art?

The company stated the patent was allowed with broad claims and without substantive narrowing due to prior art.